Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Federal Trade Commission
Boehringer Ingelheim
Chinese Patent Office
Harvard Business School
Cipla
Moodys
US Department of Justice
Queensland Health

Generated: December 18, 2018

DrugPatentWatch Database Preview

Litigation Details for Takeda Chemical v. Mylan Laboratories (S.D.N.Y. 2003)

« Back to Dashboard

Small Molecule Drugs cited in Takeda Chemical v. Mylan Laboratories
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , and ➤ Sign Up .

Details for Takeda Chemical v. Mylan Laboratories (S.D.N.Y. 2003)

Date Filed Document No. Description Snippet Link To Document
2006-02-21 121 as U.S. Patent No. 4,444,779 (“‘779 Patent”). H. The ‘902 Patent Takeda’s patent prosecutions…200 Patent. The patent, which issued on March 20, 1984, as U.S. Patent 4,438,141 (“‘141 Patent”), …issuance of U.S. Patent No. 4,287,200 (“‘200 Patent”). The application for the ‘200 Patent (“‘200 Application…Two Divisional Patents Takeda obtained two divisional patents for the ‘200 Patent. First, through…through a patent issued on July 20, 1982, as U.S. Patent No. 4,340,605 (“‘605 Patent”), Takeda received External link to document
2006-02-21 122 as U.S. Patent No. 4,444,779 (“‘779 Patent”). H. The ‘902 Patent Takeda’s patent prosecutions…200 Patent. The patent, which issued on March 20, 1984, as U.S. Patent 4,438,141 (“‘141 Patent”), …issuance of U.S. Patent No. 4,287,200 (“‘200 Patent”). The application for the ‘200 Patent (“‘200 Application…Two Divisional Patents Takeda obtained two divisional patents for the ‘200 Patent. First, through…through a patent issued on July 20, 1982, as U.S. Patent No. 4,340,605 (“‘605 Patent”), Takeda received External link to document
2006-09-20 134 Hatch-Waxman Act to Takeda’s U.S. Patent No. 4,687,777 (“‘777 Patent”), which protects the invention of… The prior art patent discussed by Kipnes is U.S. Patent No. 4,287,200 (“‘200 Patent”) and the scientific…privilege even as to the combination use patents. The combination use patents are for the use of pioglitazone …specifically mentioned in the ‘200 Patent as an example of the patented formula that has shown both low … in the ‘200 Patent and [Sohda II] render [sic] the claimed compounds of the ‘777 patent, including pioglitazone External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Healthtrust
Harvard Business School
Johnson and Johnson
Merck
US Department of Justice
McKesson
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.